View Item 

Show simple item record

Dopamine as a potential rescue therapy for refractory proteinâ losing enteropathy in Fontanâ palliated patients
dc.contributor.authorFriedland‐little, Joshua M.
dc.contributor.authorGajarski, Robert J.
dc.contributor.authorSchumacher, Kurt R.
dc.date.accessioned2017-06-16T20:11:46Z
dc.date.available2018-08-07T15:51:22Zen
dc.date.issued2017-06
dc.identifier.citationFriedland‐little, Joshua M. ; Gajarski, Robert J.; Schumacher, Kurt R. (2017). "Dopamine as a potential rescue therapy for refractory proteinâ losing enteropathy in Fontanâ palliated patients." Pediatric Transplantation 21(4): n/a-n/a.
dc.identifier.issn1397-3142
dc.identifier.issn1399-3046
dc.identifier.urihttps://hdl.handle.net/2027.42/137378
dc.description.abstractPLE is an important cause of morbidity and mortality in patients who have undergone Fontan palliation. While multiple PLE therapies have been reported, none has proved consistently effective. Patients who do not respond to â standardâ PLE therapies face poor longâ term outcomes. We report here a significant response to dopamine infusion in three patients with chronic, refractory PLE. We hypothesize that this response may be at least partially due to a dopamine effect on lymphatic receptors rather than to an augmentation of cardiac output.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherfontan operation
dc.subject.otherheart transplantation
dc.subject.otherproteinâ losing enteropathy
dc.subject.otherdopamine
dc.titleDopamine as a potential rescue therapy for refractory proteinâ losing enteropathy in Fontanâ palliated patients
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137378/1/petr12925_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137378/2/petr12925.pdf
dc.identifier.doi10.1111/petr.12925
dc.identifier.sourcePediatric Transplantation
dc.identifier.citedreferenceRychik J. Proteinâ losing enteropathy after Fontan operation. Congenit Heart Dis. 2007; 2: 288 â 300.
dc.identifier.citedreferenceFeldt RH, Driscoll DJ, Offord KP, et al. Proteinâ losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg. 1996; 112: 672 â 680.
dc.identifier.citedreferenceStamm C, Friehs I, Mayer JE Jr, et al. Longâ term results of the lateral tunnel Fontan operation. J Thorac Cardiovasc Surg. 2001; 121: 28 â 41.
dc.identifier.citedreferenceMertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Proteinâ losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg. 1998; 115: 1063 â 1073.
dc.identifier.citedreferenceJohn AS, Johnson JA, Khan M, Driscoll DJ, Warnes CA, Cetta F. Clinical outcomes and improved survival in patients with proteinâ losing enteropathy after the Fontan operation. J Am Coll Cardiol. 2014; 64: 54 â 62.
dc.identifier.citedreferenceSchumacher KR, Stringer KA, Donohue JE, et al. Fontanâ associated proteinâ losing enteropathy and plastic bronchitis. J Pediatr. 2015; 166: 970 â 977.
dc.identifier.citedreferenceCohen MI, Rhodes LA, Wernovsky G, Gaynor JW, Spray TL, Rychik J. Atrial pacing: an alternative treatment for proteinâ losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg. 2001; 121: 582 â 583.
dc.identifier.citedreferenceRychik J, Guiâ Yang S. Relation of mesenteric vascular resistance after Fontan operation and proteinâ losing enteropathy. Am J Cardiol. 2002; 90: 672 â 674.
dc.identifier.citedreferenceOstrow AM, Freeze H, Rychik J. Proteinâ losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg. 2006; 82: 695 â 700.
dc.identifier.citedreferenceParidon SM, Mitchell PD, Colan SD, et al. A crossâ sectional study of exercise performance during the first 2 decades of life after the Fontan operation. J Am Coll Cardiol. 2008; 52: 99 â 107.
dc.identifier.citedreferenceGoldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, doubleâ blind, placeboâ controlled, crossover trial. Circulation. 2011; 123: 1185 â 1193.
dc.identifier.citedreferenceMeadows J, Gauvreau K, Jenkins K. Lymphatic obstruction and proteinâ losing enteropathy in patients with congenital heart disease. Congenit Heart Dis. 2008; 3: 269 â 276.
dc.identifier.citedreferenceAntonio M, Gordo A, Pereira C, Pinto F, Fragata I, Fragata J. Thoracic duct decompression for proteinâ losing enteropathy in failing Fontan circulation. Ann Thorac Surg. 2016; 101: 2370 â 2373.
dc.identifier.citedreferenceMagdo HS, Stillwell TL, Greenhawt MJ, et al. Immune abnormalities in fontan proteinâ losing enteropathy: a caseâ control study. J Pediatr. 2015; 167: 331 â 337.
dc.identifier.citedreferenceZawieja DC. Contractile physiology of lymphatics. Lymphat Res Biol. 2009; 7: 87 â 96.
dc.identifier.citedreferenceOhhashi T, Kawai Y, Azuma T. The response of lymphatic smooth muscles to vasoactive substances. Pflugers Arch. 1978; 375: 183 â 188.
dc.identifier.citedreferenceDobbins DE. Receptor mechanisms of prenodal lymphatic constriction by dopamine. Regul Pept. 2003; 114: 7 â 13.
dc.identifier.citedreferenceTelinius N, Baandrup U, Rumessen J, et al. The human thoracic duct is functionally innervated by adrenergic nerves. Am J Physiol Heart Circ Physiol. 2014; 306: H206 â H213.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
petr12925_am.pdf
Size:
121.6KB
Format:
PDF
View/Open
Name:
petr12925.pdf
Size:
188.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.